Impact of Dapagliflozin on Symptoms and Function in Heart Failure

A pooled analysis finds benefits across the spectrum of left ventricular ejection fraction.

The sodium–glucose cotransporter-2 (SGLT-2) inhibitors have emerged as an important component of evidence-based therapy for heart failure with either reduced or preserved left ventricular ejection fraction (LVEF) based upon their impact on rates of death and heart failure–related events. This pooled analysis of patient-level data from two randomized, placebo-controlled trials assessed the impact of dapagliflozin on heart failure symptoms and physical limitation as measured by the Kansas City Cardiomyopathy Questionnaire Clinical Summary (KCCQ-CS) score.

The study sample included 587 individuals with heart failure symptoms and elevated natriuretic peptides (mean age, 67 years; 43% women; 33% Black; median LVEF, 50%) who were randomized to rec…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, MACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)